Salute e Benessere
3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy
In this newly published study, researchers at 3Z, integrated cross-species behavioral assays, Mendelian Randomization analysis, and human genetic data to demonstrate amlodipine's therapeutic potential. Key findings include:
Dr. Karl Karlsson a neuroscientist, CEO of 3Z Pharmaceuticals and Professor of Biomedical Engineering at Reykjavik University, commented on the study's impact:
Building on these findings, 3Z Pharmaceuticals is advancing a variant of the therapeutic towards clinical development, leveraging its established safety profile and precise mechanism of action to introduce transformative ADHD therapy.
Name: Karl Ægir Karlson
Title: CEO
3Z Pharmaceuticals
Email: Karlsson@3z.is
Phone: +354-8256467
Link to paper: https://www.nature.com/articles/s41386-025-02062-x
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/3z-ehf/r/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adh,c4106638
View original content:https://www.prnewswire.co.uk/news-releases/3z-pharmaceuticals-unveils-landmark-study-supporting-calcium-channel-blocker-as-a-groundbreaking-adhd-therapy-302377941.html